Adare Pharmaceuticals Celebrates Corporate Headquarters Grand Opening
Lawrenceville, New Jersey - September 28, 2016
Adare Pharmaceuticals, a private global specialty pharmaceutical company, celebrated the official opening of its Corporate Headquarters located at 1200 Lenox Drive in Lawrenceville, New Jersey.
“We are very excited to officially open our corporate office today. It is another milestone in the growth of our Company. The Lawrenceville location allows us to tap into the wealth of pharmaceutical talent in the New Jersey / Pennsylvania region and accelerates our strategic growth plans. We are appreciative of the support that we have received from the State of New Jersey through the Grow New Jersey program in the establishment of our new offices.” said John Fraher, CEO.
Mr. Fraher who officiated the ceremony recognized the Adare colleagues whose dedication to the company’s purpose had contributed to Adare’s significant growth. Dignitaries included Governor Chris Christie, and Mayor Maffei.
Building on a foundation of innovation, Adare has a strong growth trajectory through expansion of its marketed product portfolio, internal pipeline, and expertise in adding value to existing molecules. Adare has more than 40 products incorporating its proprietary technologies that are commercialized around the world.
Learn more at "www.AdarePharma.com"
Adare is a global specialty pharmaceutical company inspired to improve the lives of patients whose treatment needs are not fully addressed by current medications. We use our unique combination of experience, proprietary capabilities, and resources to create meaningful products for them. Our entrepreneurial and performance driven culture encourages us to take risks, identify promising ideas, and see those opportunities through to completion. Our collaborative spirit and dedication to developing strong partnerships provide Adare and our partners with significant advantages in competitive markets.
Adare is a high-growth company with a long history of success from concept through commercialization. Our ability to create differentiated drugs guides the identification and development of the novel products in our pipeline and our acquisition strategy.